Investigation of the effects of rapamycin on the mTOR pathway and apoptosis in metastatic and non-metastatic human breast cancer cell lines
Yazarlar (3)
Dr. Öğr. Üyesi Gülçin EKİZCELİ Bursa Uludağ Üniversitesi, Türkiye
E. T. Uluer
Manisa Celâl Bayar Üniversitesi, Türkiye
Manisa Celâl Bayar Üniversitesi, Türkiye
S. Inan
Izmir Ekonomi Üniversitesi, Türkiye
Izmir Ekonomi Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Bratislava Medical Journal (Q2) | ||
| Dergi ISSN | 0006-9248 Dergi Bilgileri (2020) | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 04-2020 |
| Kabul Tarihi | – | Yayınlanma Tarihi | 01-01-2020 |
| Cilt / Sayı / Sayfa | 121 / 4 / 308–315 | DOI | 10.4149/BLL_2020_049 |
| Makale Linki | http://www.elis.sk/download_file.php?product_id=6691&session_id=uajcnlusrli2nnh0odg8g0l382 | ||
| UAK Araştırma Alanları |
Sağlık Bilimleri
|
||
| Özet |
| AIM:The aim of this study was to analyze the effects of rapamycin treatment on apoptosis via mTOR pathway in metastatic and non-metastatic human breast cancer cell lines by immunohistochemical and TUNEL analysis. METHOD:MCF-7 and MDA-MB 231 cell lines were incubated under standard conditions forming Rapamycin and control groups. In immunohistochemical evaluation; mTOR pathway was evaluated with anti-IGF1, anti-PI3K, anti-pAKT1/2/3, anti-mTORC1, anti-mTORC2 and anti-ERK1 antibodies. The effect of apoptosis was also confirmed by TUNEL method. RESULTS:In this study, activation of PI3K/AKT/mTOR and related molecular pathways in the MDA-MB 231 and MCF-7 breast cancer cell line was evaluated and it was observed that these pathways could play a key role in cancer development. Increased apoptotic cells were observed in mTORC1 inhibition by Rapamycin administration. CONCLUSION:Targeting the mTOR pathway in breast cancer treatment may be a treatment option. In addition, the demonstration and confirmation of increased apoptosis in Rapamycin treated groups suggested that Rapamycin, an inhibitor of mTOR, is promising in the treatment of breast cancer (Tab. 2, Fig. 3, Ref. 66). |
| Anahtar Kelimeler |
| Breast cancer | MCF-7 | MDA-MB 231 | MTOR | Rapamycin |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Scopus | 6 |